Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jasper Therapeutics, Inc. - Class A Common Stock (NQ:JSPR)

0.7448 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20,042
Open 0.7448
Bid (Size) 0.7259 (200)
Ask (Size) 0.7359 (200)
Prev. Close 0.7448
Today's Range 0.7448 - 0.7448
52wk Range 0.3151 - 3.310
Shares Outstanding 736,213
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Friday's session: top gainers and losers ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers Jasper Therapeutics (NASDAQ:JSPR) stock moved upwards by 19.2% to $0.92 during Friday's regular session. The company's market cap stands at $21.6 million. Kalaris Therapeutics (NASDAQ:KLRS)... 
Via Benzinga

Performance

YTD
-59.5%
-59.5%
1 Month
+48.5%
+48.5%
3 Month
-23.9%
-23.9%
6 Month
-51.0%
-51.0%
1 Year
-76.4%
-76.4%

More News

Read More
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
The market is filled with gapping stocks in Friday's session. ↗
Via Chartmill
News headline image
Jasper Therapeutics Announces Merger with Kira Pharmaceuticals
From Jasper Therapeutics, Inc.; Kira Pharmaceuticals
Via GlobeNewswire
Top movers analysis one hour before the close of the markets on 2026-06-26: top gainers and losers in today's session. ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
Via Chartmill
Here are the top movers in Thursday's session. ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
These stocks have an unusual volume in today's session ↗
Via Chartmill
News headline image
$1 Stocks to Watch: JSPR, FTEL, BYND, TOON December 2025 More Inside
Via AB Newswire
News headline image
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via NewMediaWire
Topics Lawsuit
News headline image
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via TheNewswire.com
Topics Lawsuit
News headline image
JSPR FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that Jasper Therapeutics Investors Have Opportunity to Lead Class Action Lawsuit
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Bragar Eagel & Squire, P.C. Reminds Stockholders of Jasper, KBR, Spirit, and Molina of the Upcoming Deadlines and Urges Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Deadline Soon: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
JSPR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important November 18 Deadline in Securities Class Action – JSPR
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via NewMediaWire
Topics Lawsuit
News headline image
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via TheNewswire.com
Topics Lawsuit
News headline image
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire

Frequently Asked Questions

Is Jasper Therapeutics, Inc. - Class A Common Stock publicly traded?
Yes, Jasper Therapeutics, Inc. - Class A Common Stock is publicly traded.
What exchange does Jasper Therapeutics, Inc. - Class A Common Stock trade on?
Jasper Therapeutics, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Jasper Therapeutics, Inc. - Class A Common Stock?
The ticker symbol for Jasper Therapeutics, Inc. - Class A Common Stock is JSPR on the Nasdaq Stock Market
What is the current price of Jasper Therapeutics, Inc. - Class A Common Stock?
The current price of Jasper Therapeutics, Inc. - Class A Common Stock is 0.7448
When was Jasper Therapeutics, Inc. - Class A Common Stock last traded?
The last trade of Jasper Therapeutics, Inc. - Class A Common Stock was at 07/22/26 04:00 PM ET
What is the market capitalization of Jasper Therapeutics, Inc. - Class A Common Stock?
The market capitalization of Jasper Therapeutics, Inc. - Class A Common Stock is 548.33K
How many shares of Jasper Therapeutics, Inc. - Class A Common Stock are outstanding?
Jasper Therapeutics, Inc. - Class A Common Stock has 548K shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.